Abstract
Background Applying recent advances in medical instruments, information technology, and unprecedented data sharing into COVID-19 research revolutionized medical sciences, and causes some unprecedented analyses, discussions, and models.
Methods Modeling of this dependency is done using four classes of copulas: Clayton, Frank, Gumbel, and FGM. The estimation of the parameters of the copulas is obtained using the maximum likelihood method. To evaluate the goodness of fit of the copulas, we calculate AIC. All computations are conducted on Matlab R2015b, R 4.0.3, Maple 2018a, and EasyFit 5.6, and the plots are created on software Matlab R2015b and R 4.0.3.
Results As time passes, the number of tests increases, and the positivity rate becomes lower. The epidemic peaks are occasions that violate the stated general rule –due to the early growth of the number of tests. If we divide data of each country into peaks and otherwise, about both of them, the rising number of tests is accompanied by decreasing the positivity rate.
Conclusion The positivity rate can be considered a representative of the level of the spreading. Approaching zero positivity rate is a good criterion to scale the success of a health care system in fighting against an epidemic. We expect that if the number of tests is great enough, the positivity rate does not depend on the number of tests. Accordingly, the number and accuracy of tests can play a vital role in the quality level of epidemic data.
Key messages
- In a country, increasing the positivity rate is more representative than increasing the number of tests to warn about an epidemic peak.
- Approaching zero positivity rate is a good criterion to scale the success of a health care system in fighting against an epidemic.
- Except for the first half of the epidemic peaks, in a country, the higher number of tests is associated with a lower positivity rate.
- In countries with high test per million, there is no significant dependency between the number of tests and positivity rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no specific funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
bekrizadeh{at}pnu.ac.ir, shahriarjamshidy{at}gmail.com, mrezaei{at}kums.ac.ir
Data Availability
The main data can be found on https://www.worldometers.info/coronavirus/countries and https://ourworldindata.org/coronavirus-testing
